allo-APZ2-OTS
Phase 3Small molecule
allo-APZ2-OTS is one of 17 small molecule programs targeting Epidermolysis Bullosa. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Epidermolysis Bullosa
#DrugCompanyPhaseTrials
1Fludara
SanofiApproved
Busulfex
Akero TherapeuticsApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Accutane
CConrado Roberto Hoffmann Filho
Approved
E-Mycin
AAzurity Pharmaceuticals
Approved
Epidiolex
Jazz PharmaceuticalsPhase 2
Primsol
CConrado Roberto Hoffmann Filho
Phase 2
8-Mop
TTherakos, Inc., a Mallinckrodt Company
Phase 2
Oleogel-S10
Chiesi Farmaceutici S.p.A.Phase 3
Tetracyclin
SShandong University
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for allo-APZ2-OTS. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRHEACELL GmbH & Co. KG